Surgical management of high-risk, localized prostate cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Urology
Link
http://www.nature.com/articles/s41585-020-00384-7.pdf
Reference150 articles.
1. Reese, A. C., Pierorazio, P. M., Han, M. & Partin, A. W. Contemporary evaluation of the National Comprehensive Cancer Network prostate cancer risk classification system. Urology 80, 1075–1079 (2012).
2. Hall, M. D., Schultheiss, T. E., Farino, G. & Wong, J. Y. C. Increase in higher risk prostate cancer cases following new screening recommendation by the US preventive services task force (USPSTF). J. Clin. Oncol. 33, 143–143 (2015).
3. Mahal, B. A. et al. Use of active surveillance or watchful waiting for low-risk prostate cancer and management trends across risk groups in the United States, 2010–2015. JAMA 321, 704–706 (2019).
4. Tosoian, J. J. et al. Active surveillance of grade group 1 prostate cancer: long-term outcomes from a large prospective cohort. Eur. Urol. 77, 675–682 (2020).
5. Klotz, L. et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J. Clin. Oncol. 33, 272–277 (2015).
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Nanotherapeutics for prostate cancer treatment: A comprehensive review;Biomaterials;2024-03
2. Surgical Management and Considerations for Patients with Localized High-Risk Prostate Cancer;Current Treatment Options in Oncology;2024-01
3. Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial;JNCI: Journal of the National Cancer Institute;2023-09-07
4. Impact of Multiparametric Magnetic Resonance Imaging for the Prediction of Extraprostatic Extension According to the National Comprehensive Cancer Network Risk Stratification in Prostate Cancer;Journal of Urologic Oncology;2023-07-31
5. Androgen deprivation therapy plus abiraterone or docetaxel as neoadjuvant therapy for very-high-risk prostate cancer: a pooled analysis of two phase II trials;Frontiers in Pharmacology;2023-06-26
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3